How to Budget for a Multi-Week Tesamorelin Research Protocol

Budgeting for a multi-week tesamorelin research protocol starts with a single number: the cost per milligram, not the price stamped on the vial’s label. A listing that looks cheap per vial can end up more expensive over a full protocol if the vial size forces a lab to buy more material than a given allocation schedule actually consumes. Working from per-mg cost, rather than per-vial price, is what lets a budget line up with the actual quantity a multi-week schedule requires.

Why Per-Vial Price Is the Wrong Starting Point

Vial listings vary in size across suppliers — 2 mg, 5 mg, 10 mg, and larger bulk vials are all common on tesamorelin listings. Comparing two suppliers by sticker price alone ignores that a $90 vial containing 2 mg of peptide is a different cost structure than a $180 vial containing 10 mg. The first works out to $45 per mg; the second to $18 per mg. Any multi-week budget built on sticker price rather than this derived figure will misestimate total spend, sometimes by a wide margin.

The per-mg figure is calculated the same way regardless of vial size:

Cost per mg = listed vial price ÷ mg of peptide in the vial

That single ratio is the unit a protocol budget should be built around, because it is the one figure that stays comparable across differently sized vials and differently priced suppliers.

Building the Budget: Total Mg Needed First

Before pricing anything, a multi-week protocol needs to be expressed in total milligrams, not total vials. That means multiplying the per-day mg allocation used in the research design by the number of days the protocol runs:

Total mg required = mg allocated per day × number of days

Only after this total is known does it make sense to work out how many vials that requires, and only then does the true cost of the protocol become clear — because vials are sold as whole units, and a protocol’s mg requirement rarely divides evenly into a vial’s mg content.

Worked Example: An 8-Week Protocol

Take a listing priced at $180 for a 10 mg vial, and a research design that allocates 2 mg per day over an 8-week (56-day) protocol.

Step 1 — cost per mg. $180 ÷ 10 mg = $18.00 per mg.

Step 2 — total mg for the protocol. 2 mg/day × 56 days = 112 mg total.

Step 3 — vials required. 112 mg ÷ 10 mg per vial = 11.2 vials. Vials cannot be purchased as a fraction, so the actual purchase rounds up to 12 vials.

Step 4 — actual spend versus theoretical spend. 12 vials × $180 = $2,160 actually spent. 112 mg × $18.00/mg = $2,016 theoretical cost for the exact mg used. The $144 difference is the cost of 8 mg of unused peptide left over in the 12th vial (8 mg × $18.00/mg = $144).

That leftover-mg gap is the single most common reason a multi-week budget runs over what a simple per-mg calculation predicts. A protocol that lands close to a whole-vial multiple wastes little; a protocol that lands just past a whole-vial multiple, as in this example, always leaves a partially used vial on the shelf.

Table: How Vial Size Changes the Same Protocol

The same 112 mg requirement, priced against different vial sizes from the per-mg figures above, shows why vial size selection matters as much as per-mg price when building a budget.

Vial size	Price per vial	Cost per mg	Vials needed for 112 mg	Actual spend	Leftover mg
2 mg	$90	$45.00	56	$5,040	0 mg
5 mg	$110	$22.00	23 (112 ÷ 5 = 22.4)	$2,530	3 mg
10 mg	$180	$18.00	12 (112 ÷ 10 = 11.2)	$2,160	8 mg

Smaller vials carry a higher per-mg price on most listings, since packaging, reconstitution supplies, and handling costs are spread across less peptide. Larger vials lower the per-mg figure but can leave more unused material if the protocol length does not divide evenly into the vial’s mg content. A budget built for a specific protocol length should check both the per-mg price and the leftover-mg math before choosing a vial size, not just the headline price.

Reconstitution Math Affects the Same Budget

Once a vial size is chosen, reconstitution volume determines how the mg total translates into the volume drawn on a research syringe, which is useful for confirming that the days-per-vial assumption used in the budget is correct.

A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields a concentration of 5 mg/mL, or 5,000 mcg/mL. On a U-100 insulin syringe, where 1 mL equals 100 units, that concentration works out to 0.05 mg (50 mcg) per unit. A 2 mg daily allocation corresponds to 40 units per draw (40 units × 50 mcg/unit = 2,000 mcg = 2 mg), and at that draw size, one 10 mg vial covers 5 days (10 mg ÷ 2 mg/day). Over 56 days, that is the same 11.2-vials figure calculated in Step 3 — a useful cross-check on the mg-total method above.

Changing the bacteriostatic water volume changes concentration and therefore units per draw, but not the total mg consumed or the total cost. More water lowers concentration and raises the unit count per draw; less water does the opposite. Either way, per-mg cost stays fixed, because it is set by the vial’s price and mg content, not by how it is reconstituted.

Purity and COA Notes That Belong in the Same Budget Line

A per-mg figure is only meaningful if the mg content on the label reflects what is actually in the vial. Listings that publish a certificate of analysis (COA) alongside stated purity give a budget builder a way to check that the mg-per-vial figure is verified rather than assumed. A listing without a COA, or with a purity figure that cannot be traced to a specific batch, introduces uncertainty into every downstream number in the budget — cost-per-mg, vials required, and total spend are all only as reliable as the mg content they are built from.

Background: Why Multi-Week Protocols Are Common in This Research Class

Tesamorelin belongs to a class of growth hormone releasing hormone (GHRH) analogs studied for decades in relation to pituitary and hypothalamic signaling. Foundational work on human growth hormone releasing factor established dosing and administration patterns still referenced in this research area, as documented in a 1986 clinical study of human growth hormone releasing factor in normal adults and patients. Anatomical work has also mapped how GHRH-producing neurons interact with somatostatin signaling in the human hypothalamus, detailed in a 2015 anatomical study on GHRH neuron distribution in the human hypothalamus, which helps explain why this class of protocol is typically designed to run over multiple weeks. Broader use of GHRH-class secretagogues as research tools is reviewed in a 2001 review of growth hormone secretagogues used as diagnostic tools in disease states. None of this changes the budgeting math above — it explains why protocol lengths here are commonly expressed in weeks, the unit a per-mg budget is built around.

For labs that want to check reconstitution and per-unit math independently of the worked example above, PeptCalc is a free calculator that runs the same concentration and units-per-draw arithmetic.

Summary

A multi-week tesamorelin research protocol is budgeted correctly by starting with cost per mg, not the price on the vial. Multiply the per-day mg allocation by the protocol length to get total mg required, divide by vial size to get vials needed, and round up — then check the leftover mg against the per-mg price to see how much of the budget goes to unused material rather than the protocol itself. Reconstitution volume changes units per draw but not total cost, and a COA-backed purity figure is what makes every number in the calculation trustworthy in the first place.